Incendia Therapeutics is a biotechnology startup founded in 2018 and based in the United States. The company focuses on discovering and developing novel anti-cancer medicines that reprogram the tumor microenvironment to overcome immune exclusion barriers prevalent in many cancers. Their lead program, PRTH-101, is a first-in-class humanized monoclonal antibody designed to disrupt the extracellular matrix barrier created by tumors, enabling immune cells to infiltrate and attack the tumor. This innovative approach is set to enter Phase 1 clinical trials, with a pipeline of preclinical projects targeting other aspects of the tumor microenvironment also in development. Incendia's strategy includes a precision oncology approach complemented by proprietary AI technology to identify biomarkers and guide patient selection strategies for clinical applications. With this unique combination of drug development and precision medicine, Incendia Therapeutics aims to bring the right medicines to the right patients, making significant strides in the field of cancer treatment.
There is no investment information
No recent news or press coverage available for Incendia Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
